Gregory Lambrecht
Fondateur chez Intrinsic Therapeutics, Inc.
Profil
Gregory H.
Lambrecht is the founder of Intrinsic Therapeutics, Inc. since 1999, where he holds the title of Executive Director.
He is also the founder of Viacor, Inc., Coravin, Inc. Gregory's former jobs include being a Principal at Pfizer Inc. and Vice President-Marketing at Stryker Corp.
Mr. Lambrecht received his undergraduate and graduate degrees from Massachusetts Institute of Technology in 1990 and 1993, respectively.
Postes actifs de Gregory Lambrecht
| Sociétés | Poste | Début |
|---|---|---|
Intrinsic Therapeutics, Inc.
 Intrinsic Therapeutics, Inc. Medical SpecialtiesHealth Technology Intrinsic Therapeutics, Inc. develops device-based therapies for soft-tissue injuries of the spine. It offers surgeons and patients better options for treating painful disc herniations that cause sciatica and low back pain. The company was founded by Gregory H. Lambrecht in 1999 and is headquartered in Woburn, MA. | Fondateur | 01/01/1999 |
Coravin, Inc.
 Coravin, Inc. Beverages: AlcoholicConsumer Non-Durables Coravin, Inc. develops new technology for tapping bottles of wine. Its system allows users to access and pour their favorite wines by the glass without pulling the cork. The firm offers wine access needles, triggers, capsules, clamps, needle assortment kits, carry cases, vintage needles, faster pour needles, standard replacement needles, wine bottle sleeve on bottles, and replacement base products. The company was founded by Greg Lambrecht and Josh Makower in 2011 and is headquartered in Burlington, MA. | Fondateur | - |
Anciens postes connus de Gregory Lambrecht
| Sociétés | Poste | Fin |
|---|---|---|
Viacor, Inc.
 Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | Fondateur | 04/04/2012 |
| PFIZER, INC. | Corporate Officer/Principal | - |
| STRYKER CORPORATION | Sales & Marketing | - |
Formation de Gregory Lambrecht
| Massachusetts Institute of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| STRYKER CORPORATION | Health Technology |
| PFIZER, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Intrinsic Therapeutics, Inc.
Intrinsic Therapeutics, Inc. Medical SpecialtiesHealth Technology Intrinsic Therapeutics, Inc. develops device-based therapies for soft-tissue injuries of the spine. It offers surgeons and patients better options for treating painful disc herniations that cause sciatica and low back pain. The company was founded by Gregory H. Lambrecht in 1999 and is headquartered in Woburn, MA. | Health Technology |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | Health Technology |
Coravin, Inc.
Coravin, Inc. Beverages: AlcoholicConsumer Non-Durables Coravin, Inc. develops new technology for tapping bottles of wine. Its system allows users to access and pour their favorite wines by the glass without pulling the cork. The firm offers wine access needles, triggers, capsules, clamps, needle assortment kits, carry cases, vintage needles, faster pour needles, standard replacement needles, wine bottle sleeve on bottles, and replacement base products. The company was founded by Greg Lambrecht and Josh Makower in 2011 and is headquartered in Burlington, MA. | Consumer Non-Durables |
